Patents Assigned to Genentech
  • Injection monitoring device with delivery signature
    Patent number: 11565054
    Abstract: Drug delivery systems and methods of use thereof for recording administration of a drug dose to a subject are provided. Aspects of the invention include a syringe stopper rod comprising a sensor component that is configured to detect a delivery signature, and to transmit a report comprising a drug dose completion signal to a data management component, e.g., a mobile computing device.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: January 31, 2023
    Assignee: Genentech, Inc.
    Inventor: Steven N. Roe
  • Isoquinolines as inhibitors of HPK1
    Patent number: 11566003
    Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: January 31, 2023
    Assignee: Genentech, Inc.
    Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good
  • CYCLIC PEPTIDE ANTIBIOTICS
    Publication number: 20230025834
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 26, 2023
    Applicant: Genentech, Inc.
    Inventors: Guosheng WU, Emily J. HANAN, Marie-Gabrielle BRAUN, Sharada S. LABADIE, Keira GARLAND, Richard M. PASTOR, Paul Anthony GIBBONS, Yuhong FU, Yun-Xing CHENG
  • METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA
    Publication number: 20230027184
    Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
    Type: Application
    Filed: September 15, 2022
    Publication date: January 26, 2023
    Applicants: GENENTECH, INC., ABBVIE INC.
    Inventors: Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
  • SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO
    Publication number: 20230028651
    Abstract: A manufacturing process to a bis-mesylate salt 1b of the pan-RAF inhibitor 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide. The process features a number of efficient key reactions, including a robust and scalable Pd-catalyzed carbonylation reaction to generate thienopyrimidine 2 and a highly chemoselective PtN/C-catalyzed nitro group reduction to access penultimate intermediate 7. The final amide coupling of 7 and 2 was accomplished by a mild and safe protocol employing N,N,N?,N?-tetramethylchloroformamidinium hexafluorophosphate (TCFH) as the coupling reagent, to produce a 1:1 adduct of the freebase and THF. The adduct afforded compound 1b with excellent yield, purity, and form stability on a multikilogram production scale after reaction with MsOH and recrystallization. The methods are able to produce a compound having upwards of 95% purity.
    Type: Application
    Filed: June 28, 2022
    Publication date: January 26, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Francis GOSSELIN, Stefan G. KOENIG, Eduardo V. MERCADO-MARIN, Andreas STUMPF, Daniel ZELL, Haiming ZHANG, Stephan BACHMANN, Diane E. CARRERA, Michael E. DALZIEL, Yonghui GE, Jie ZHANG, Raphael BIGLER, Laure Elizabeth Simone FINET, Regis Jean Georges MONDIERE, Yuki NAKAGAWA
  • Sulfonylurea compounds as inhibitors of interleukin-1 activity
    Patent number: 11560391
    Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: January 24, 2023
    Assignee: Genentech, Inc.
    Inventors: Jeffrey A. Stafford, James M. Veal, Lynnie Lin Trzoss, Christopher McBride, Richard M. Pastor, Steven Thomas Staben, Craig Stivala, Matthew Volgraf
  • INHALABLE DRY POWDER AND AEROSOL FORMULATIONS OF JAK INHIBITORS
    Publication number: 20230016791
    Abstract: wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: August 24, 2022
    Publication date: January 19, 2023
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Marie Grandner, Daniel G.M. Shore, Marian C. Bryan
  • Anti-MIC antibodies and methods of use
    Patent number: 11555076
    Abstract: The invention provides anti-MIC antibodies and methods of using the same.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: January 17, 2023
    Assignee: Genentech, Inc.
    Inventors: Twyla Noelle Lombana, Christoph Spiess, Jeong Kim, Evangeline Toy, Jill Schartner, Zhengmao Ye, Jack Bevers, III, Ryan Cook, Marissa Matsumoto, Amy Berkley
  • Anti-Tau antibodies and methods of use
    Patent number: 11555065
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: January 17, 2023
    Assignees: AC Immune SA, Genentech, Inc.
    Inventors: Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
  • USE OF GENETIC ALGORITHMS TO DETERMINE A MODEL TO IDENTITY SAMPLE PROPERTIES BASED ON RAMAN SPECTRA
    Publication number: 20230009725
    Abstract: Techniques are disclosed for using a genetic algorithm to identify a processing pipeline that transforms spectra into a form usable to generate predicted characteristics of corresponding samples. The genetic algorithm is used to generate and evaluate multiple candidate solutions specifying various pre-processing and machine-learning-processing configurations. The processing pipeline is defined based on the candidate solutions.
    Type: Application
    Filed: September 19, 2022
    Publication date: January 12, 2023
    Applicant: GENENTECH, INC.
    Inventors: Dana Lauren McDaniel, Elvira Kadaub, Bingchuan Wei, Andrew James Maier, Gordon Edward Magill
  • Methods for preparing antibody drug conjugates
    Patent number: 11547762
    Abstract: The subject matter described herein is directed to methods of preparing certain antibody-drug conjugates (ADCs) wherein the antibody is linked to the drug through a linker, wherein the drug contains a heteroaryl group having a secondary nitrogen, and the linker is attached to the drug via the secondary nitrogen. The resulting conjugates are useful in treating various diseases and conditions.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: January 10, 2023
    Assignee: Genentech, Inc.
    Inventors: Thomas Pillow, Peter Dragovich
  • Compounds and compositions for the inhibition of NAMPT
    Patent number: 11547701
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: January 10, 2023
    Assignees: Valo Health, Inc., Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA
    Publication number: 20230000889
    Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
    Type: Application
    Filed: June 7, 2022
    Publication date: January 5, 2023
    Applicants: GENENTECH, INC., ABBVIE INC.
    Inventors: Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
  • BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF
    Publication number: 20230002391
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
    Type: Application
    Filed: June 6, 2021
    Publication date: January 5, 2023
    Applicant: Genentech, Inc.
    Inventors: Snahel Patel, Gregory Hamilton, Craig Stivala, Huifen Chen, Blake Daniels
  • ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
    Publication number: 20230000977
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Application
    Filed: August 22, 2022
    Publication date: January 5, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. BENYUNES, Graham Alexander ROSS
  • AUTOMATED DETECTION OF TUMORS BASED ON IMAGE PROCESSING
    Publication number: 20230005140
    Abstract: Methods and systems disclosed herein relate generally to processing images to estimate whether at least part of a tumor is represented in the images. A computer-implemented method includes accessing an image of at least part of a biological structure of a particular subject, processing the image using a segmentation algorithm to extract a plurality of image objects depicted in the image, determining one or more structural characteristics associated with an image object of the plurality of image objects, processing the one or more structural characteristics using a trained machine-learning model to generate estimation data corresponding to an estimation of whether the image object corresponds to a lesion or tumor associated with the biological structure, and outputting the estimation data for the particular subject.
    Type: Application
    Filed: August 30, 2022
    Publication date: January 5, 2023
    Applicant: Genentech, Inc.
    Inventors: Gregory Zelinsky FERL, Richard Alan Duray CARANO, Kai Henrik BARCK, Jasmine PATIL
  • THERAPEUTIC COMPOUNDS
    Publication number: 20230002396
    Abstract: The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, and compositions and uses thereof. The compounds are useful as inhibitors of the YAP:TEAD protein:protein interaction. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various YAP:TEAD-mediated disorders, including cancer.
    Type: Application
    Filed: May 26, 2022
    Publication date: January 5, 2023
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Jason Robert Zbieg
  • Injection monitoring device
    Patent number: 11541187
    Abstract: Drug delivery systems, devices and methods of use for recording a drug dose completion signal in a data management system are provided. Aspects of the invention include drug delivery systems comprising a syringe stopper rod that comprises a sensor component comprising a wireless transmitter module and an activation component configured to activate the sensor component when the syringe stopper rod has completed a delivery stroke, wherein the wireless transmitter module is configured to transmit a report comprising a drug dose completion signal when the sensor component is activated.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: January 3, 2023
    Assignee: Genentech, Inc.
    Inventors: Sherri Biondi, Geraint Davies, Steven N. Roe
  • FLT3 ligand fusion proteins and methods of use
    Patent number: 11542308
    Abstract: The invention provides an effectorless immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: January 3, 2023
    Assignee: Genentech, Inc.
    Inventors: Yichin Liu, Christine Carine Moussion, Travis William Bainbridge, Iraj Hosseini, Gregory Alan Lazar, Sivan Cohen, Christopher Charles Kemball, Jill M. Schartner
  • MULTISPECIFIC ANTIGEN-BINDING PROTEINS
    Publication number: 20220409725
    Abstract: Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 29, 2022
    Applicant: Genentech, Inc.
    Inventors: Paul CARTER, Christoph SPIESS, Yiyuan YIN, Jianhui ZHOU, Wendy SANDOVAL, Jacob CORN, Michael DILLON